Dr. Lal Path Labs growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+12.3%+11.1%
EBITDA+12.5%+16.9%
Net Income+3.6%+28.3%
EPS (adj.)+3.6%+28.3%
Total Assets+15.8%+9.7%
Total Equity+15.2%+14.3%
Free Cash Flow−10.2%+4.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LALPATHLAB₹1,911.70

Dr. Lal Path Labs Ltd.

· Pharma & Health
₹ CrorePeersMETROPOLISVIJAYATHYROCARENATCOPHARMNEULANDLABNHCOHANCESAILIFEMcap ₹32,040 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+12.3+11.1
EBITDA+12.5+16.9
Net Income+3.6+28.3
EPS (adj.)+3.6+28.3
Total Assets+15.8+9.7
Total Equity+15.2+14.3
Free Cash Flow-10.2+4.0
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.